Evidence map›Paper›PMID 36147336›Full record

ArticleFrontiers in pharmacology2022

Corrigendum: Impact of the COVID-19 pandemic on the diagnosis of

Mariana do Rosário Souza, Wandklebson Silva da Paz, Vinícius Barbosa Dos Santos Sales, Gleidson Felipe Hilario de Jesus, Débora Dos Santos Tavares, Shirley V M Almeida Lima, Álvaro Francisco Lopes Sousa, Enaldo Vieira de Melo, Rodrigo Feliciano do Carmo, Carlos Dornels Freire de Souza and 1 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Mariana do Rosário SouzaHealth Science Graduate Program, Universidade Federal de Sergipe, São Cristóvão, Brazil.
Wandklebson Silva da PazParasitic Biology Graduate Program, Universidade Federal de Sergipe, São Cristóvão, Brazil.
Vinícius Barbosa Dos Santos SalesDepartment of Medicine, Universidade Federal de Sergipe, Aracaju, Brazil.
Gleidson Felipe Hilario de JesusDepartment of Medicine, Universidade Federal de Sergipe, Aracaju, Brazil.
Débora Dos Santos TavaresDepartment of Health Education, Universidade Federal de Sergipe, Lagarto, Brasil.
Shirley V M Almeida LimaDepartment of Nursing, Universidade Federal de Sergipe, Lagarto, Brasil.
Álvaro Francisco Lopes SousaGlobal Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal.
Enaldo Vieira de MeloDepartment of Medicine, Universidade Federal de Sergipe, Aracaju, Brazil.
Rodrigo Feliciano do CarmoCollege of Pharmaceutical Sciences, Federal University of Vale do São Francisco (UNIVASF), Petrolina, Brazil.
Carlos Dornels Freire de SouzaDepartment of Medicine, Universidade Federal de Alagoas, Arapiraca, Brazil.
Márcio Bezerra-SantosHealth Science Graduate Program, Universidade Federal de Sergipe, São Cristóvão, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fphar.2022.891711.].

Indexed as

COVID-19COVID-19 pandemicend TB strategyglobal healthtuberculosis

Identifiers

PMID36147336
PMCPMC9486810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.